No one-trick pony in oncology, Merck’s cancer footprint is expanding

Listen to the article
5 min

This audio is auto-generated. Please let us know if you have feedback.

Merck & Co.’s presence in cancer has long rotated around its crown jewel checkpoint inhibitor Keytruda. But with the blockbuster approaching a series of patent cliffs, Merck is writing its next chapter in cancer R&D.

“In our prior era, everything was about Keytruda,” Dr. Alex Snyder, the company’s senior vice…